Biogen Buys Apellis for $5.6B to Expand Kidney Drugs

This is a live story built from multiple sources. It may evolve quickly.

Coverage meter • 1 min window

Back to home Open top source

B bloomberg.com

What’s included

Top recent items from this story.

1 items • 1 unique links

Bloomberg Markets 4 days ago • bloomberg.com

Biogen Buys Apellis for $5.6B to Expand Kidney Drugs

Bloomberg's Michelle Davis joins Dani Burger on "Bloomberg Deals." Biogen has agreed to acquire Apellis Pharmaceuticals for $5.6 billion, expanding its treatments in immunology and rare diseases in one of the company’s l…

Open